NCT02125240 - Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

July 31, 2021

Conditions

EGFR Positive Non-small Cell Lung CancerAdenocarcinoma

Interventions

DRUG

Icotinib

125 mg three times daily (375 mg per day) by mouth

DRUG

Placebo

1 tablet three times daily by mouth

Trial Locations (11)

100000

RECRUITING

Beijing Chaoyang Hospital, Beijing

100005

RECRUITING

Beijing Hospital, Beijing

RECRUITING

Beijing Union Medical College Hospital, Beijing

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Science, Beijing

100029

RECRUITING

China-japan friendship hospital in Beijing, Beijing

100034

NOT_YET_RECRUITING

Peking University First Hospital, Beijing

100044

RECRUITING

Peking University People's Hospital, Beijing

100048

RECRUITING

304 Hospital of PLA, Beijing

100053

NOT_YET_RECRUITING

Xuanwu Hospital, Capital Medical University, Beijing

100853

NOT_YET_RECRUITING

People's Liberation Army General Hospital (301 Hospital), Beijing

101149

RECRUITING

Capital Medical University, Beijing Chest Hospital, Beijing